CPSA 2013
Connecting Patients and Subject Numbers Through Analysis
October 7-10, 2013
Sheraton Bucks County Hotel
Langhorne, PA
Synopsis
Tuesday, 12:00 pm - 1:00 pm
Lunch/Roundtable
Sponsored by Shimadzu
Monoclonal antibodies (MAbs) are a fast growing class of human pharmaceuticals, with current approved drugs and clinical trials in numerous therapeutic indications including oncology, inflammatory diseases, cardiology, viral infection, allergy, organ transplantation and tissue growth/repair. The majority of these current therapeutic antibodies are humanized or human Immunoglobulins (IgGs). Fast and accurate new analysis platforms are needed to characterize these therapeutic antibodies, especially as interest in specific post translational modifications, including glycoforms, increases. This workshop will demonstrate how manual, bench-top sample preparation steps used in antibody and protein analyses can be replace with a faster, more reproducible, fully-automated sample prep platform. Incorporating the Perfinity Workstation into therapeutic monoclonal antibody and fusion protein analysis dramatically increases assay reproducibility while enabling complete digestion of plasma/sera samples in less than six minutes. Coupling the Perfinity to the latest generation of ultra fast mass spectrometry (LCMS-8050 triple quadrupole) with attogram sensitivity and scan speeds and polarity switching, enables traditional peptide-based SRM analysis workflows taking over 18 hours to now be performed in approximately 40 minutes. This integrated platform offers exciting new opportunities for the analysis of therapeutic antibodies and fusion proteins and their PTM-variants, and provides an automated analysis platform for the monitoring of alternative biotechnological production systems.
Return to program